vs
EXACT SCIENCES CORP（EXAS）与FULLER H B CO（FUL）财务数据对比。点击上方公司名可切换其他公司
FULLER H B CO的季度营收约是EXACT SCIENCES CORP的1.0倍（$892.0M vs $878.4M），FULLER H B CO净利率更高（7.5% vs -9.8%，领先17.3%），EXACT SCIENCES CORP同比增速更快（23.1% vs -2.8%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $68.9M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 5.0%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
H.B.富勒公司是总部位于美国明尼苏达州圣保罗的跨国粘合剂制造企业，全球第四大粘合剂及密封剂生产商。公司拥有超过20000种产品，广泛应用于建筑、工程、电子、卫生用品、食品包装等领域，在26个国家设有81座生产基地，2024年员工规模约7500人。
EXAS vs FUL — 直观对比
营收规模更大
FUL
是对方的1.0倍
$878.4M
营收增速更快
EXAS
高出25.9%
-2.8%
净利率更高
FUL
高出17.3%
-9.8%
自由现金流更多
EXAS
多$51.5M
$68.9M
两年增速更快
EXAS
近两年复合增速
5.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $892.0M |
| 净利润 | $-86.0M | $67.2M |
| 毛利率 | 70.1% | 32.0% |
| 营业利润率 | -9.4% | 12.3% |
| 净利率 | -9.8% | 7.5% |
| 营收同比 | 23.1% | -2.8% |
| 净利润同比 | 90.1% | 21.3% |
| 每股收益（稀释后） | $-0.45 | $1.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFUL
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | $892.0M | ||
| Q2 25 | $811.1M | $898.1M | ||
| Q1 25 | $706.8M | — | ||
| Q4 24 | $713.4M | — | ||
| Q3 24 | $708.7M | $917.9M | ||
| Q2 24 | $699.3M | — | ||
| Q1 24 | $637.5M | $810.4M |
净利润EXASFUL
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | $67.2M | ||
| Q2 25 | $-1.2M | $41.8M | ||
| Q1 25 | $-101.2M | — | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | $55.4M | ||
| Q2 24 | $-15.8M | — | ||
| Q1 24 | $-110.2M | $31.0M |
毛利率EXASFUL
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | 32.0% | ||
| Q2 25 | 69.3% | 31.9% | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | 30.0% | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | 29.5% |
营业利润率EXASFUL
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | 12.3% | ||
| Q2 25 | -0.3% | 11.1% | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | 11.4% | ||
| Q2 24 | -3.8% | — | ||
| Q1 24 | -16.7% | 8.3% |
净利率EXASFUL
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | 7.5% | ||
| Q2 25 | -0.1% | 4.7% | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | 6.0% | ||
| Q2 24 | -2.3% | — | ||
| Q1 24 | -17.3% | 3.8% |
每股收益（稀释后）EXASFUL
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | $1.22 | ||
| Q2 25 | $-0.01 | $0.76 | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | $0.98 | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.60 | $0.55 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $122.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $2.0B |
| 总资产 | $5.9B | $5.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASFUL
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | $122.5M | ||
| Q2 25 | $858.4M | $96.8M | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | $131.4M | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | $165.2M |
股东权益EXASFUL
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.5B | $1.9B | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $3.2B | $1.8B | ||
| Q2 24 | $3.2B | — | ||
| Q1 24 | $3.1B | $1.8B |
总资产EXASFUL
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | $5.2B | ||
| Q2 25 | $5.8B | $5.1B | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $6.7B | $5.0B | ||
| Q2 24 | $6.7B | — | ||
| Q1 24 | $6.4B | $4.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $99.0M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $68.9M |
| 自由现金流率自由现金流/营收 | 13.7% | 7.7% |
| 资本支出强度资本支出/营收 | 3.6% | 3.4% |
| 现金转化率经营现金流/净利润 | — | 1.47× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASFUL
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | $99.0M | ||
| Q2 25 | $89.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | $169.4M | ||
| Q2 24 | $107.1M | — | ||
| Q1 24 | $-82.3M | $47.4M |
自由现金流EXASFUL
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | $68.9M | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | $99.9M | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | $4.1M |
自由现金流率EXASFUL
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | 7.7% | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | 10.9% | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | 0.5% |
资本支出强度EXASFUL
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | 3.4% | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | 7.6% | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | 5.3% |
现金转化率EXASFUL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FUL
| Hygiene Health And Consumable Adhesives | $386.1M | 43% |
| Engineering Adhesives | $272.3M | 31% |
| Building Adhesives Solutions | $233.7M | 26% |
